Rewind Therapeutics: Rewind Therapeutics raises funding to further lead programme into clinical development
The funding round has seen participation of current investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven. As part of the investment, The post Rewind Therapeutics raises funding to further lead programme into clinical development appeared first on Pharmaceutical Business review.
Read full article »
Rewind Therapeutics is a Belgium-based biotechnology company that researches and develops remyelinating therapies for the treatment of multiple sclerosis.
Read more